SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 1 of 26
Word Count: 1322
Character Count: 8434

Document Content:

the aggregate market value of our common stock held by non-affiliates is less than $75,000,000. During the 12 calendar months prior to, and including, the date of this prospectus, we have not sold any securities pursuant to General Instruction I.B.6 of Form S-3. Investing in our securities involves risk. You should carefully consider the risks that we refer you to under the section captioned “Risk Factors” in this prospectus on page 7 before buying our securities. Should we offer any of the securities described in this prospectus, we will provide you with the specific terms of the particular securities being offered in supplements to this prospectus. You should read this prospectus and any supplement, together with additional information described under the headings “Additional Information” and “Incorporation of Certain Information by Reference” carefully before you invest. This prospectus may not be used to sell securities unless accompanied by a prospectus supplement.

We may sell these securities
directly to our stockholders or to other purchasers or through agents on our behalf or through underwriters or dealers as designated from
time to time. If any agents or underwriters are involved in the sale of any of these securities, the applicable prospectus supplement
will provide the names of the agents or underwriters and any applicable fees, commissions or discounts.

We are a “smaller reporting
company” as defined under the federal securities laws and, under applicable SEC rules, we have elected to comply with certain reduced
public company reporting and disclosure requirements.

Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.

The date of this prospectus is           ,

TABLE OF CONTENTS

ABOUT THIS PROSPECTUS	ii

PROSPECTUS SUMMARY	1

RISK FACTORS	7

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS	8

USE OF PROCEEDS	9

THE SECURITIES WE MAY OFFER	10

DESCRIPTION OF CAPITAL STOCK	11

DESCRIPTION OF DEBT SECURITIES	14

DESCRIPTION OF STOCK WARRANTS	20

DESCRIPTION OF SUBSCRIPTION RIGHTS	21

DESCRIPTION OF UNITS	22

FORMS OF SECURITIES	23

PLAN OF DISTRIBUTION	25

LEGAL MATTERS	28

EXPERTS	28

DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES	29

ADDITIONAL INFORMATION	30

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE	31

Synergy CHC Corp. is referred
to herein as “Synergy,” “the Company,” “we,” “us” and “our,” unless the context
indicates otherwise.

You may only rely on the information
contained in this prospectus and the accompanying prospectus or that we have referred you to. We have not authorized anyone to provide
you with different information. This prospectus and any prospectus supplement do not constitute an offer to sell or a solicitation of
an offer to buy any securities other than the securities offered by this prospectus and the prospectus supplement. This prospectus and
any prospectus supplement do not constitute an offer to sell or a solicitation of an offer to buy any securities in any circumstances
in which such offer or solicitation is unlawful. Neither the delivery of this prospectus or any prospectus supplement nor any sale made
hereunder shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus
or such prospectus supplement or that the information contained by reference to this prospectus or any prospectus supplement is correct
as of any time after its date.

ABOUT THIS PROSPECTUS

This prospectus is part of
a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a “shelf” registration
process. Under this shelf registration process, we may from time to time offer and sell, in one or more offerings, any or all of the securities
described in this prospectus, separately or together, up to an aggregate offering price of $100 million. This prospectus provides you
with a general description of our securities being offered. When we issue the securities being offered by this prospectus, we will provide
a prospectus supplement that will contain specific information about the terms of that offering. The prospectus supplement may also add,
update or change information contained in this prospectus. You should read both this prospectus and any prospectus supplement together
with additional information described under the heading “Additional Information” and “Incorporation of Certain Information
by Reference.”

PROSPECTUS SUMMARY

The following summary highlights
some information from this prospectus. It is not complete and does not contain all of the information that you should consider before
making an investment decision. You should read this entire prospectus, including the “Risk Factors” section on page 7
and the disclosures to which that section refers you, the financial statements and related notes and the other more detailed information
appearing elsewhere or incorporated by reference into this prospectus before investing in any of the securities described in this prospectus.

Our Company

We are a provider of consumer health care, beauty, and lifestyle products.
Our current brand portfolio consists of two marquee brands, FOCUSfactor, a clinically-tested brain health supplement (this study
was performed independently and is not related to any FDA-approved investigational new drug (IND) application) that has been shown
to improve memory, concentration and focus, and Flat Tummy, a lifestyle and wellness brand that provides a suite of nutritional products
to help women achieve their nutrition and weight management goals. For the year ended December 31, 2024, FOCUSfactor represented
88% of our net revenue and Flat Tummy was 12%. For the nine months ended September 30, 2025, FOCUSfactor represented 86% of our net revenue
and Flat Tummy represented 14%. Our products are sold through some of the nation’s leading club, mass drug, and other retailers
such as Costco, Amazon.com, Walmart, Walgreens, CVS, BJ’s Wholesale Club, Publix Supermarkets, The Vitamin Shoppe, Target.com, H-E-B,
Meijer, and Albertson’s. Additionally, we have expanded into Canada and the United Kingdom.

We built our brand portfolio
through strategic acquisitions. We acquired the FOCUSfactor brand in January 2015 for cash consideration of $6.0 million, including
earnout. In November 2015, we acquired our second marquee brand, Flat Tummy, for AUD 10.0 million (approximately $7.0 million),
using a mix of cash and stock. Our capital structure following the acquisitions of our key brands in 2015 has been highly levered, and
our focus has been on paying our debt and, as a result, we do not have the resources to grow our business. We have grown our FOCUSfactor
brand from 3 SKUs at acquisition to over 34 SKUs, and our Flat Tummy Brand from 1 SKU to 13 SKUs. We use the term SKU, or stock-keeping unit,
to refer to a product with a unique UPC (Universal Product Code), which is the barcode used to identify products.

Our growth from 2022 to the present was driven by expanded distribution
of our FOCUSfactor product line to some of our major retailers, such as Costco, CVS and Walmart, among others. This expansion included
SKUs within our FOCUSfactor vision line as well as focus and energy Ready-to-Drink (RTD). As a result, net revenue for the year ended
December 31, 2024 was $34.8 million, a decrease of $8 million, or 19%, compared to net revenue for the year ended December 31,
2023 of $42.8 million. Net revenue for the nine months ended September 30, 2025 was $24.3 million, a decrease of $0.3 million, or
1% compared to net revenue of $24.6 million for the nine months ended September 30, 2024. FOCUSfactor net revenue decreased 2% from $21.3
million for the nine months ended September 30, 2024 to $20.8 million for the nine months ended September 30, 2025. FOCUSfactor net revenue
for the year ended December 31, 2024 was $30.8 million, a 17.0% decrease from FOCUSfactor net revenue for the year ended December 31,
2023 of $37.2 million. During the nine months ended September 30, 2025 we also had revenue from a license agreement of $2.9 million
related to expansion in selected foreign markets, which we anticipate to be an ongoing source of revenue.

Our Brands